DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Summary for Patent: 9,738,905
|Title:||Vector for expressing NC protein of HIV and method for producing NC protein using the same|
|Abstract:||The present invention relates to a vector for expressing an NC protein of HIV and a method for producing an NC protein using the same. More particularly, the present invention relates to a vector for expressing an NC protein of HIV, in which an intron sequence and an mRNA stability element in the downstream of NC gene are sequentially linked, and a method for producing an NC protein using the same. The vector for expressing an NC protein of HIV of the present invention, in which an intron sequence and an mRNA stability element in the downstream of NC gene are sequentially linked, can express a wild type NC protein in animal cells, and has an effect of improving the expression efficiency, as compared to a known art.|
|Inventor(s):||You; Ji Chang (Seoul, KR)|
|Assignee:||You; Ji Chang (Seoul, KR) AVIXGEN INC. (Seoul, KR)|
|Patent Claims:||1. A vector for expressing a nucleocapsid (NC) protein of Human Immunodeficiency Virus (HIV), comprising a) any one sequence selected from the group consisting of an
SV40 19s mRNA intron sequence of SEQ ID NO:8, a modified SV40 16S mRNA intron sequence of SEQ ID NO:9 and a .beta.-globin intron sequence of SEQ ID NO: 10, b) a gene encoding for an HIV NC protein of SEQ. ID NO. 4, selected from the group consisting of
SEQ ID NO:3, 5, 6 AND 7, and c) an mRNA stability element wherein the genes of a)-c) are sequentially linked.
2. The vector for expressing an NC protein of HIV according to claim 1, wherein the mRNA stability element is any one selected from the group consisting of RRE (Rev response element), WPRE (woodchuck post-transcriptional regulatory element), .beta.-actin 3'-UTR (untranslated regions) and RSV stability element (Rous sarcoma virus stability element).
3. The vector according to claim 1, wherein the vector for expressing an NC protein of HIV has a cleavage map disclosed in FIG. 2 or FIG. 4.
4. An isolated cell transformed with the vector of any one of claim 2, or 3.
5. The transformed cell according to claim 4, wherein the cell is a COS-7 or 293T cell.
6. A method for producing an NC protein of HIV, comprising the step of culturing the transformed cell of claim 4.
7. A codon-optimized HIV NC polynucleotide for high expression in mammalian cells, comprising a nucleotide sequence represented by any one selected from the group consisting of SEQ. ID NO. 3, SEQ. ID NO. 5, SEQ. ID NO. 6 and SEQ. ID NO. 7.
Summary for Patent: Start Trial
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|South Korea||10-2006-0131392||Dec 20, 2006|
|South Korea||10-2006-0131393||Dec 20, 2006|
|PCT Filed||December 20, 2007||PCT Application Number:||PCT/KR2007/006694|
|PCT Publication Date:||June 26, 2008||PCT Publication Number:||WO2008/075911|
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||001||1986-06-04||Start Trial||You; Ji Chang (Seoul, KR) AVIXGEN INC. (Seoul, KR)||2026-12-20||RX||search|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||002||1986-06-04||Start Trial||You; Ji Chang (Seoul, KR) AVIXGEN INC. (Seoul, KR)||2026-12-20||RX||search|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||003||1986-06-04||Start Trial||You; Ji Chang (Seoul, KR) AVIXGEN INC. (Seoul, KR)||2026-12-20||RX||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Publication Date|
|World Intellectual Property Organization (WIPO)||2008075911||Jun 26, 2008|
|United States of America||2010047865||Feb 25, 2010|
|South Korea||101158755||Jun 22, 2012|
|South Korea||101158756||Jun 22, 2012|
|South Korea||20080057750||Jun 25, 2008|
|South Korea||20080057751||Jun 25, 2008|
|Japan||2010512782||Apr 30, 2010|
|>Country||>Patent Number||>Publication Date|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.